These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 8687976)

  • 1. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone turnover in children with vitamin D deficiency rickets before and during treatment.
    Baroncelli GI; Bertelloni S; Ceccarelli C; Amato V; Saggese G
    Acta Paediatr; 2000 May; 89(5):513-8. PubMed ID: 10852183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.
    Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J
    Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
    Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
    Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
    Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
    J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paget's disease of bone treated with a five day course of oral tiludronate.
    Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P
    Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
    Lems WF; Gerrits MI; Jacobs JW; van Vugt RM; van Rijn HJ; Bijlsma JW
    Ann Rheum Dis; 1996 May; 55(5):288-93. PubMed ID: 8660101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.